APR 27·GlobeNewswireMed
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Dyadic International, Inc. has announced a strategic partnership with Rabian BV to develop affordable rabies prophylactics and vaccines using Dyadic's proprietary C1 protein production platform. This collaboration, partially funded by Eurostars, aims to address the global burden of rabies, especially in lower- and middle-income countries. Dyadic will receive an equity stake, fully funded R&D costs, and royalties from the commercialization of these new products.